Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Acquires DNA Consumables Portfolio from GE Healthcare

NEW YORK (GenomeWeb News) – IntegenX today said that it has acquired a portfolio of DNA consumables products from GE Healthcare Bio-Sciences' subsidiary SV Corp.

The acquisition provides Pleasanton, Calif.-based IntegenX with an IP estate covering capillary electrophoresis, separation, sample preparation, and separation matrix technologies, according to IntegenX CEO Stevan Jovanovich.

IntegenX will take over supplying capillaries and matrix to "the more than 100 existing users of GE's MegaBace sequencers," the firm said. Financial and other terms of the deal were not disclosed.

IntegenX intends to integrate the acquired products into its RapidHit 200 Human DNA Identification System, which is scheduled for launch later this year.

The RapidHIT 200 is a sample-to-profile biometric system for real-time human DNA analysis, and according to IntegenX is the first fully automated DNA identification technology that can produce DNA profiles from buccal swabs or other human samples in less than 90 minutes.

Late last year, IntegenX raised $40 million in a Series C round to support further development and commercialization of the system.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.